]>
IRCT2017041514085N4 IRCT 2017-08-01 Vice Chancellar of Research of Guilan University of Medical Sciences The effect of Probiotics on control of clinical features of Bronchiectasis The effect of Probiotics on control of clinical features and exacerbation of Bronchiectasis 2017-03-21 anticipated 60 Complete https://irct.ir/trial/13785 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: After obtaining an informed consent from the subjects, they will be randomly categorized in either the control group (group A) or the placebo group (group B). In this way, the number will be assigned randomly to the patients who enter the study.This number identifies a person in one group (A is control group and B is placebo group). 2-3 bronchiectasis. Intervention 1: Intervention group 1(intervention group)will received routine drugs for treatment, they will treated with lactocare for 6 months. Intervention 2: Intervention group 2 (control group ) will received routine drugs for treatment and placebo during 6 months.
public Dr Shabnam Ziapour
Razi Hospital, Sardar Jangal Avenue
Rasht Iran (Islamic Republic of) +98 133542460 shabnam_ziapour@yahoo.com Inflammatory Lung Disease Research Center scientific Dr Ali Alavi
Razi Hospital, Sardar Jangal Avenue
Rasht Iran (Islamic Republic of) +98 13 3354 2460 ali_alavi@gums.ac.ir Inflammatory Lung Disease Research Center Iran (Islamic Republic of) Inclusion criteria: More than 18 years, Not being Pregnant; Exclusion criteria: Cardiovascular diseases; Diabetes; Use of immunosuppressive agents; Bronchiectasis due to foreign body or tumor; Disable to do spirometry 18 years no limit Both j47 Bronchiectasis Treatment - Drugs Placebo Intervention group 1(intervention group)will received routine drugs for treatment, they will treated with lactocare for 6 months Intervention group 2 (control group ) will received routine drugs for treatment and placebo during 6 months Severity of cough. Timepoint: The same 6 month of last year and at during of intervention. Method of measurement: by asking the person. Amount of sputum. Timepoint: The same 6 month of last year and before of intervention and end of sixth months. Method of measurement: by asking the person. Severity of dyspnea. Timepoint: The same 6 month of last year and at during of intervention. Method of measurement: by asking the person base on MRC scale. Results of sputum culture. Timepoint: before of intervention and end of sixth month. Method of measurement: smear and anti biogram. FEV1, FVC, FEV1/FVC. Timepoint: before of intervention and end of sixth month. Method of measurement: spirometry. Body mass index. Timepoint: before of intervention and end of sixth month. Method of measurement: weight over square of height. Need of prophylactic antibiotic for disease exacerbation. Timepoint: during of intervention. Method of measurement: by asking the person. Rate of hospitalizations. Timepoint: during of intervention. Method of measurement: by asking the person. Rate of exacerbation of disease. Timepoint: during of intervention. Method of measurement: by asking the person. Zist Takhmir Tehran Vice Chancellar of Research of Guilan University of Medical Sciences Zist Takhmir Tehran Approved 2017-02-25 Research Council of Guilan University of Medical Sciences Vice Chancellor of Research of Guilan University of Medical Sciences, Gaz Avenue Rasht Iran (Islamic Republic of)